Recon: AstraZeneca to buy Fusion in targeted radiation deal valued at $2B; Seelos ALS treatment fails in mid-stage trial
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States